WHO Drug Information Vol. 25, No. 2, 2011
WHO Drug Information Vol. 25, No. 2, 2011
WHO Drug Information Vol. 25, No. 2, 2011
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>WHO</strong> <strong>Drug</strong> <strong>Information</strong> <strong>Vol</strong>. <strong>25</strong>, <strong>No</strong>. 2, <strong>2011</strong> Proposed INN: List 105cantuzumabum ravtansinum #cantuzumab ravtansinecantuzumab ravtansinecantuzumab ravtansinaimmunoglobulin G1-kappa, anti-[Homo sapiens MUC1 sialylatedcarbohydrate, tumour-associated (CA242, cancer antigen 242)],humanized monoclonal antibody conjugated to maytansinoid DM4;gamma1 heavy chain (1-449) [humanized VH (Homo sapiensIGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T(114)) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-449)], (222-219')-disulfide with kappa light chain (1’-219’) [humanized V-KAPPA(Homo sapiens IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L (109),D1<strong>25</strong>>E (110), I126>L (111)) [11.3.9] (1'-112') -Homo sapiensIGKC*01 (113'-219')]; (228-228":231-231")-bisdisulfide dimer;conjugated, on an average of 3 to 4 lysyl, to maytansinoid DM4 [N 2’ -deacetyl-N 2’ -(4-mercapto-4-methyl-1-oxopentyl)-maytansine] via thereducible SPDB linker [N-succinimidyl 4-(2-pyridyldithio)butanoate]For the ravtansine part, please refer to the document "INN forpharmaceutical substances: Names for radicals, groups and others"*antineoplasticimmunoglobuline G1-kappa, anti-[Homo sapiens glycane sialylé deMUC1, associé à des tumeurs (CA242, antigène du cancer 242)],anticorps monoclonal humanisé conjugué au maytansinoïde DM4;chaîne lourde gamma1 (1-449) [VH humanisé (Homo sapiensIGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T(114)) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-449)], (222-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPAhumanisé (Homo sapiens IGKV2-28*01 (82.00%) -IGKJ3*01 V124>L(109), D1<strong>25</strong>>E (110), I126>L (111)) [11.3.9] (1'-112') -Homo sapiensIGKC*01 (113'-219')]; dimère (228-228":231-231")-bisdisulfure;conjugué, sur 3 à 4 lysyl en moyenne, au maytansinoïde DM4 [N 2' -déacétyl-N 2' -(4-mercapto-4-méthyl-1-oxopentyl)-maytansine] via lelinker SPDB réductible [4-(2-pyridyldithio)butanoate deN-succinimidyle]Pour la partie ravtansine, veuillez vous référer au document "INN forpharmaceutical substances: Names for radicals, groups andothers"*.antinéoplasiqueinmunoglobulina G1-kappa, anti-[Homo sapiens glicano sialilo deMUC1, asociado al tumor (CA242, antígeno del cancer 242)]anticuerpo monoclonal humanizado conjugado con el maitansinoideDM4;cadena pesada gamma1 (1-449) [VH humanizada (Homo sapiensIGHV7-4-1*02 (76.50%) -(IGHD)-IGHJ2*01 R120>Q (111), L123>T(114)) [8.8.12] (1-119) -Homo sapiens IGHG1*01 (120-449)], (222-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPAhumanizada (Homo sapiens IGKV2-28*01 (82.00%) -IGKJ3*01V124>L (109), D1<strong>25</strong>>E (110), I126>L (111)) [11.3.9] (1'-112') -Homosapiens IGKC*01 (113'-219')]; dímero (228-228":231-231")-bisdisulfuro; conjugado, en 3-4 grupos lisil por término medio, con elmaitansinoide DM4 [N 2' -desacetil-N 2' -(4-mercapto-4-metil-1-oxopentil)-maitansina] mediante el conector SPDB reducible[4-(2-piridilditio)butanoato de N-succinimidilo]Para la fracción ravtansina, se ruega referirse al documento "INN forpharmaceutical substances: Names for radicals, groups andothers"*.antineoplásico159
Change language